Orgenesis Provides Year End Business Update
15 avr. 2024 17h07 HE
|
Orgenesis Inc.
Major transformation underway commencing with recent acquisitionreasserting full ownership and control over Octomera Secured a $2.3 million investment from a group including sophisticated healthcare...
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
10 avr. 2024 12h00 HE
|
Orgenesis Inc.
ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) -- Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global...
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
18 mars 2024 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced...
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
13 mars 2024 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., March 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced...
Orgenesis Inc. Announces $2.3 Million Private Placement
04 mars 2024 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., March 04, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), announced today...
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
29 févr. 2024 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that...
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
31 janv. 2024 09h15 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced it...
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
14 nov. 2023 08h30 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Provides Business Update for the Third Quarter of 2023
13 nov. 2023 16h15 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene...
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
08 nov. 2023 09h00 HE
|
Orgenesis Inc.
GERMANTOWN, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (“Orgenesis”) (Nasdaq: ORGS), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs),...